Cyp asx

Morningstar Investor users sign in here. Skip to Content. Market Centre.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Cyp asx

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow Volatile share price over the past 3 months. Shareholders have been diluted in the past year. Currently unprofitable and not forecast to become profitable over the next 3 years. Has less than 1 year of cash runway. New minor risk - Financial position Feb New major risk - Financial position Aug See more updates Recent updates.

Investing guides. Top Stories.

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast MCA to manufacture cell therapy products, including mesenchymal stem cells , on a commercial scale. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Financial Times Close.

Key events shows relevant news articles on days with large price movements. Mesoblast Ltd. MSB 7. Starpharma Holdings Ltd. SPL 3. Anteris Technologies Ltd.

Cyp asx

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow

Me and bobby mcgee chords

In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Adviser Spotlight. Make up to three selections, then save. Trade our derivatives market. Last Reported Earnings Dec 31, ASX Market Report. Show more Personal Finance link Personal Finance. Show more Companies link Companies. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Average volume All rights reserved. For Advisers. Financial Times Close. About the company. Market Report.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved.

Volatile share price over the past 3 months. Subscribe to our newsletters. Morningstar Investment Conference for Individual Investors. Investing guides. Learn to invest in DLT as a Service. All content on FT. Please check your inbox. All markets data located on FT. Any information that you receive via FT. Open 0.